Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Present and future molecular testing of lung carcinoma.

Advances in anatomic pathology - 1 Mar 2014

Dacic Sanja, Nikiforova Marina N

Abstract excerpt

The rapid development of targeted therapies has tremendously changed clinical management of lung carcinoma patients and set the stage for similar developments in other tumor types. Many studies have been published in the past decade in search for the most acceptable method of assessment for predi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Anaplastic Lymphoma Kinase
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Forecasting

Share to Molecular Diagnostic Techniques

Share to Molecular Targeted Therapy

Share to Patient Selection

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 24508692
DOI: 10.1097/PAP.0000000000000012

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24508692-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Present and future molecular testing of lung carcinoma.PMID 24508692Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Molecular testing and personalized treatment of lung cancer.Semantic proximity Read ↗

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Semantic proximity Read ↗

Molecular diagnostics of lung carcinomas.Semantic proximity Read ↗

Lung cancer genotype-based therapy and predictive biomarkers: present and future.Semantic proximity Read ↗

Lung cancer biomarkers, targeted therapies and clinical assays.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Trends in Lung Cancer Molecular Testing.Semantic proximity Read ↗

Recent Advances in Personalized Lung Cancer MedicineSemantic proximity Read ↗

Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression.Semantic proximity Read ↗

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.